News Release

Study Further Positions Lonza's UC-II® Undenatured Type II Collagen as a Leader in the Crowded Joint-Health Market

Basel, Switzerland, 15 February 2018 – Research published in *Osteoarthritis & Cartilage* provides further validation for Lonza’s UC-II® undenatured type II collagen as a leading brand in the joint health ingredient space. The study, “Oral Administration of Undenatured Native Chicken Type II Collagen (UC-II) Diminished Deterioration of Articular Cartilage in a Rat Model of OA,” is available online for download.

“This study represents a major milestone for the UC-II® brand, and it validates our efforts to develop new paradigms for joint health products for the aging population, while also addressing the needs of an expanding group of younger, active, health-conscious consumers,” said Dr. James Lugo, Chief Scientific Officer of the Consumer Health & Nutrition Business Unit of Lonza. “These new results complement previously published clinical data on the UC-II® ingredient, which demonstrate statistically significant beneficial effects for healthy subjects who develop knee-joint discomfort following strenuous exercise. This research also furthers our understanding of the mechanisms through which the UC-II® brand elicits its beneficial effects.”

The research was conducted utilizing a rat model for osteoarthritis (OA), which resembles some of the characteristics of human OA, including articular cartilage deterioration, bone-spur formation and the loss of knee mechanical function, which results in significant changes in walking gait.

The dose of the UC-II® ingredient selected for the study represents the clinically tested human equivalent dose of 40 mg per day. As this small size and once-per-day frequency provides an efficacious dose, it may improve consumer compliance. This benefit, in combination with the ingredient’s foundation of research, provides manufacturers with new, significant consumer benefits compared with traditional products in the joint health market.

UC-II® undenatured type II collagen has been clinically studied in healthy adults¹ and has been shown to help improve joint comfort, mobility and flexibility in people with OA.²³ Additionally, it has been shown to be statistically significantly more effective than the combination of glucosamine and chondroitin, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).²

Lonza’s UC-II® ingredient and method of manufacture are patented (US Patents, 7,846,487 and 7,083,820; EP Patent EP 1 435 906; Canadian Patent CA 2459981C; and Japanese Patent JP 4800574 B2 additional granted patents and pending patent applications). The method of using UC-II® undenatured type II collagen is also patented (US patent 9,066,926 and other pending patent applications).

About Lonza Consumer Health & Nutrition

Lonza Consumer Health & Nutrition combines expertise in high-quality, science-backed ingredients with formulation know-how and industry-leading capsule and encapsulation technologies to create innovative solutions for consumer health and nutrition companies. Our deep clinical knowledge supports specialty ingredients with proven performance, enabling customers to address consumer health concerns via new, differentiated health products.

We apply consumer market insights and our extensive experience in pharmaceutical delivery science to help our customers improve bioavailability, targeted delivery, swallowability, taste and odor masking of their nutritionalas. Our technology enables unique combination products and


Consumer Health & Nutrition provides visually appealing dosage forms that meet the expectations of today’s health-conscious consumers.

We also bring exceptional service capabilities, global regulatory expertise, and expert technical service to support our customers in quickly delivering differentiated nutritional products to market. More information is available at www.Lonza.com.

About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications
Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.